Diffusion Pharmaceuticals (DFFN) Phase 3 study with trans sodium crocetinate, or TSC plus standard of care of patients with inoperable glioblastoma showed increased survival. according to Tuesday release.
Six out of seven patients who received high dose TSC treatment are still alive, with a median survival time of 14.3 months, compared with 9.2 months in previous studies.
The recent study could be the basis for US Food and Drug Administration’s approval, according to the statement.
Glioblastoma is a type of astrocytoma, a cancer that forms from star-shaped cells in the brain called astrocytes.